论文部分内容阅读
采用低剂量顺铂（一次剂量＜50mg／m2）联合化疗方案治疗晚期乳腺癌42例。顺铂给药方法为30mg／d1～5·3w或40mg／d1～3·3w，给药期间给予水化、地塞米松及胃复安等一般对症治疗。其中用CMFP方案（环膦酰胺（CTX）十氨甲喋呤（MTX）＋5氟脲嘧啶（5—FU）＋顺铂（DDP）14例；CFP方案（CTX＋5—FU＋DDP）20例；CAP方案（CTX＋阿霉素（ADM）＋DDP）8便。总有效率59．5％，中位缓解期8个月，中位生存期18个月。初治病人有效率68％，复治病人有效率41．2％。对软组织、肝及肺转移者有效率分别为53．3％（8／15）、66．7％（4／6）及50％（6／12）；对骨转移者治效较差，有效率为12．5％（1／8）。本组59．5％的病人出现恶心、呕吐，仅1例出现肾功能异常，停药后恢复正常。提示低剂量顺铂联合化疗方案治疗晚期乳腺癌疗效较好，可作为一线方案应用。
Low-dose cisplatin (one dose <50 mg/m2) combined with chemotherapy regimen was used to treat 42 cases of advanced breast cancer. Cisplatin administration method is 30mg/d 1~5·3w or 40mg/d 1~3·3w. During the administration period, general symptomatic treatment such as hydration, dexamethasone and metoclopramide is given. Among them, the CMFP protocol (cyclophosphamide (CTX) methotrexate (MTX) + 5 fluorouracil (5-FU) + cisplatin (DDP) 14 cases; CFP program (CTX + 5-FU + DDP) 20 cases; CAP program (CTX + mold (ADM)+DDP)8. The total effective rate is 59.5%, the median remission period is 8 months, the median survival period is 18 months, the initial treatment patient efficiency is 68%, and the retreatment patient efficiency is 41. 2%.The effective rates for soft tissue, liver and lung metastases were 53.3% (8/15), 66.7% (4/6) and 50% (6/12), respectively; Poor, the effective rate was 12.5% (1/8), 59.5% of patients in this group had nausea and vomiting, only 1 case had abnormal renal function and returned to normal after discontinuation, suggesting low-dose cisplatin combined with chemotherapy The treatment of advanced breast cancer has good curative effect and can be used as a first-line treatment.